Abu Dhabi Health Department Signs MoU with Xlife Sciences to Boost Life-Sciences Sector

By HEOR Staff Writer

September 12, 2023

The Department of Health – Abu Dhabi (DoH) and Swiss firm Xlife Sciences have signed a Memorandum of Understanding (MoU) in a bid to fortify the Emirate’s life-sciences sector. The agreement, which was signed at the Department’s Headquarters, aims to enhance innovation, funding opportunities for life sciences start-ups, and clinical research within the Emirate.

The collaboration is part of DoH’s ongoing efforts to establish Abu Dhabi as a global hub for healthcare and life sciences. It will provide incubation training, mentoring, and commercialisation support to innovators, while also exploring the possibility of a joint funding framework with local ecosystem partners.

Dr. Asma Ibrahim Al Mannaei, Executive Director of Research and Innovation Centre at the DoH, expressed her delight at the collaboration, citing it as a step towards addressing global healthcare challenges and reinforcing the development of Abu Dhabi’s life sciences sector.

Xlife Sciences, represented by CEO Oliver R. Baumann, has established their UAE presence through a partnership with ICEBERG Capital, a company based in Abu Dhabi Global Market (ADGM) and regulated by Financial Services Regulatory Authority (FSRA). ICEBERG Capital will be handling the company’s investment strategy and fund management, further enhancing the life sciences ecosystem in Abu Dhabi.

Abdullah Al Weshah, Managing Director – ICEBERG Capital, commented on the collaboration, expressing excitement at the prospect of supporting the Abu Dhabi Life-Sciences ecosystem and looking forward to establishing a joint funding framework to support start-ups, founders, and projects.

This agreement further cements Abu Dhabi’s position as a global life sciences hub and an incubator for healthcare innovation, while spearheading the transformation of the regional healthcare ecosystem through leveraging sciences and technology. 

Reference url

Recent Posts

AI Governance Pharmaceuticals: Ensuring Ethical AI Integration in the Medicines Lifecycle

By HEOR Staff Writer

December 9, 2025

In the pharmaceutical industry, AI governance in pharmaceuticals is crucial for harnessing artificial intelligence's potential in drug discovery, clinical trials, and patient monitoring. How can pharma companies integrate AI ethically across the medicines lifecycle? This article draws on a recent...
Repurposing Off-Patent Medicines: Insights from the EU Pilot Initiative

By HEOR Staff Writer

December 8, 2025

EU Pilot Initiative for Repurposing Off-Patent Medicines: Core Outcomes and Regulatory Support Repurposing off-patent medicines offers a promising pathway to address unmet medical needs, p...
Innovations in Haematology Cell Therapy at ASH 2025

By HEOR Staff Writer

December 5, 2025

Advancing Haematology Cell Therapy Innovations at ASH 2025 AstraZeneca is significantly advancing haematology cell therapy with its largest-ever presence at the 67th American Society of Hematology (ASH) Annual Meeting and E...